| 1 |
A potent and selective PARP14 inhibitor decreases protumor macrophage gene expression and elicits inflammatory responses in tumor explants
Laurie B. Schenkel et al. · Cell chemical biology
Open access |
11 Mar 2021 |
80 |
| 2 |
From Genotype to Phenotype—A Review of Kabuki Syndrome
Kelly K. Barry, Michaelangelo Tsaparlis, Deborah Hoffman et al. · Genes
Open access |
29 Sep 2022 |
69 |
| 3 |
Pharmacokinetics of novel Fc-engineered monoclonal and multispecific antibodies in cynomolgus monkeys and humanized FcRn transgenic mouse models
Delphine Valente, Christine Mauriac, Thorsten Schmidt et al. · mAbs
Open access |
2020 |
32 |
| 4 |
XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer
Kurt A. Jenkins, Miso Park, Magali Pederzoli-Ribeil et al. · Journal for ImmunoTherapy of Cancer
Open access |
Dec 2023 |
21 |
| 5 |
IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer
Timothy Anthony Yap, Alberto Bessudo, Erika Paige Hamilton et al. · Journal for ImmunoTherapy of Cancer
Open access |
Mar 2022 |
19 |
| 6 |
Hydrophilic Interactions Dominate the Inverse Temperature Dependence of Polypeptide Hydration Free Energies Attributed to Hydrophobicity
Dheeraj S. Tomar, Michael E. Paulaitis, Lawrence R. Pratt et al. · The Journal of Physical Chemistry Letters
|
10 Nov 2020 |
18 |
| 7 |
XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
Ekta P. Patel et al. · Molecular Cancer Therapeutics
Open access |
29 Nov 2023 |
14 |
| 8 |
The molecular basis of Human FN3K mediated phosphorylation of glycated substrates
Ankur Garg, Kin Fan On, Yang Fan Xiao et al. · Nature Communications
Open access |
22 Jan 2025 |
11 |
| 9 |
System Size Dependence of Hydration-Shell Occupancy and Its Implications for Assessing the Hydrophobic and Hydrophilic Contributions to Hydration
Dilip N. Asthagiri, Dheeraj S. Tomar · The Journal of Physical Chemistry B
|
9 Jan 2020 |
11 |
| 10 |
Terminal alkyne formation by a pyridoxal phosphate-dependent enzyme
Jason B. Hedges, Jorge A. Marchand, Carla Calvó‐Tusell et al. · Nature Chemical Biology
|
25 Jun 2025 |
7 |
| 11 |
Target binding triggers hierarchical phosphorylation of human Argonaute-2 to promote target release
Brianna Bibel, Elad Elkayam, Steve Silletti et al. · bioRxiv (Cold Spring Harbor Laboratory)
PreprintOpen access |
6 Jan 2022 |
3 |
| 12 |
Solution structure and dynamics of the mitochondrial‐targeted GTPase ‐activating protein (GAP) VopE by an integrated NMR / SAXS approach
Kyle P. Smith, Woonghee Lee, Marco Tonelli et al. · Protein Science
Open access |
9 Feb 2022 |
2 |
| 13 |
Analysis of Mutational Signatures Using the mutSignatures R Library
Damiano Fantini, Joshua J. Meeks · Methods in molecular biology
Book chapter |
2023 |
1 |
| 14 |
El pódcast para democratizar y difundir contenido de calidad en cardiología. El proyecto Mio-Cardio Podcast
Aldo L. Schenone · REC CardioClinics
|
8 Mar 2022 |
1 |
| 15 |
Dying in the year after surviving: a perspective on elevated all-cause mortality among opioid overdose survivors
Robert B. Raffa, Albert Dahan, Joseph V. Pergolizzi et al. · The American Journal of Drug and Alcohol Abuse
|
18 Sep 2026 |
0 |
| 16 |
POSTER: MPN-1206: Discovery and Characterization of DMR-001, an Fc-Null, Half-Life–Optimized Monoclonal Antibody Selectively Targeting Mutant Calreticulin
Byron Kwan, Shannon Elf, Alexandra Grassian et al. · Clinical Lymphoma Myeloma & Leukemia
|
Aug 2026 |
0 |
| 17 |
Development and characterization of a long-acting allosteric growth hormone receptor antagonist for acromegaly
Katherine Kurylo, Page R. Bouchard, Mark Milton et al. · Endocrinology
Open access |
3 Aug 2026 |
0 |
| 18 |
Development of an antisense oligonucleotide targeting EFEMP1 in models relevant to macular degeneration
William P. Miller et al. · Molecular Therapy — Nucleic Acids
Open access |
21 Jul 2026 |
0 |
| 19 |
A droplet microfluidics-based platform for generating target-specific, natively-paired immune libraries and identifying potent and developable antibodies
Anusuya Ramasubramanian et al. · Scientific Reports
Open access |
3 Jan 2026 |
0 |
| 20 |
#2438 Discovery and characterization of JADE101, an ultra-high affinity, half-life extended anti-APRIL monoclonal antibody for the treatment of IgAN
Erin L. Filbert, Brandon Gufford, Byong Ha Kang et al. · Nephrology Dialysis Transplantation
Open access |
Oct 2025 |
0 |
| 21 |
1015 ORKA-002, a novel extended half-life monoclonal antibody targeting IL-17A/F for the treatment of psoriatic disease
Bethany Matthews Kwan, Joseph Frank Merola, Andrew Blauvelt et al. · Journal of Investigative Dermatology
Open access |
21 Jul 2025 |
0 |
| 22 |
ENA-001, an Agnostic Respiratory Stimulant, Reverses Xylazine-Fentanyl Induced Respiratory Depression in Rats
Thomas Lloyd Miller, Robert Raffa, George C. Dungan et al. · Drug and Alcohol Dependence
|
Feb 2025 |
0 |
| 23 |
New Rat Study Suggests a Biologic Basis for Higher Fentanyl Mortality in Men Than Women
Robert B. Raffa, Joseph V. Pergolizzi, Jeannette Mathews et al. · Drug and Alcohol Dependence
|
Feb 2025 |
0 |
| 24 |
A novel and potent MICA/B antibody is therapeutically effective in KRAS LKB1 mutant lung cancer models
Ryan R Kowash, Manoj Kumar Sabnani, Laura T. Gray et al. · bioRxiv (Cold Spring Harbor Laboratory)
PreprintOpen access |
31 Jul 2024 |
0 |
| 25 |
758 APG777, a high-affinity humanized IgG1 monoclonal antibody targeting IL-13, demonstrates prolonged half-life and pSTAT6 inhibition in non-human primates
E. Zhu, Jae‐Min Oh, Lukas Dillinger et al. · Journal of Investigative Dermatology
|
19 Jul 2024 |
0 |
| 26 |
Safety and Tolerability of Ascending Doses of ENA-001: A Novel Respiratory Stimulant, for the Intended Management of Pharmacologically-Induced Respiratory Depression
Errol M Gould, Thomas Lloyd Miller, Joseph V. Pergolizzi · Drug and Alcohol Dependence
|
Jul 2024 |
0 |
| 27 |
Novel ‘Agnostic’ Pharmacologic Approach to Polysubstance Overdose
Thomas Lloyd Miller, Amanda M. Bunting, Michael E Schatman et al. · Drug and Alcohol Dependence
|
Jul 2024 |
0 |
| 28 |
SAXS/MC studies of the mixed-folded protein Cdt1 reveal monomeric, folded over conformations
Kyle P. Smith, Srinivas Chakravarthy, Amit Rahi et al. · bioRxiv (Cold Spring Harbor Laboratory)
PreprintOpen access |
3 Jan 2024 |
0 |
| 29 |
133P Phase I/II study of XTX101: A masked, tumor-activated Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors
Diwakar Davar, John George Knecht, Andrae Lavon Vandross et al. · Immuno-Oncology Technology
Open access |
Dec 2023 |
0 |
| 30 |
Own Your Career: Essential Skills Needed in the Biotech Workforce
Tim Hunt, Anjali Angelika Sarkar · GEN Biotechnology
|
Aug 2022 |
0 |